References

1. Perl, ER. Causalgia, pathologic pain, and adrenergic receptors. Proc. Natl. Acad. Sci. USA 1999;96:7664-7667.
   
2. Mayer DJ, Mao J, Holt J, Price DD. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. USA 1999;96:7731-7736.
   
3. Yaksh TL, Hua X-Y, Kalcheva I, et al. The spinal biology in humans and animals of pain states generatedby persistent small afferent imput. Proc. Natl. Acad. Sci. USA 1999;96:7680-7686.
   
4. Fitzgerald M, Jennings E. The postnatal development of spinal sensory processing. Proc. Natl. Acad. Sci. USA 1999;96:7719-7722.
   
5. Watkins LR, Maier SF. Implications of immune-to-brain communication for sickness and pain. Proc. Natl. Acad. Sci. USA 1999;96:7710-7713.
   
6. Woolf CJ, Costigan M. Transcriptional and posttranscriptional plasticity and the generation of inflammatory pain. Proc. Natl. Acad. Sci. USA 1999;96:7723-7730.
   
7. Baillie-Hamilton PF, Chemical toxins: a hypothesis to explain the global obesity epidemic. J. Alt. Comp. Med. 2002;8(2):185-192.
   
8. EPA Booklet: The Inside Story, A Guide to Indoor Air Quality (September 1988, EPA/400/1-88/004).
   
9. Davis DL, Dinse GE, Hoel DG. Decreasing cardiovascular disease and increasing cancer among whites in the United States from 1973 through 1987: good news and bad news. JAMA 1994;271(16):431-347.
   
10. Vikki McInnis-Shaw. Liver Disease Medical Glossary. Hepatitis Central.
    
11. Parris M. Kidd, Ph.D. Phosphatidylcholine: A Superior Protectant Against Liver Damage. Alt Med Rev 1996;1(4):258-274
    
12. Hanin I, Ansell GB: Lecithin: Technological, Biological, and Therapeutic Aspects. New York: Plenum Press, 1987
    
13. Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease. National Institute of Neurological Disorders and Stroke 94-N-0205
    
14. Hypothesis for Cause of Memory Loss in Alzheimer's Disease Proposed. National Institute on Aging.
    
15. Chung SY. Moriyama T. Et al. Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia. J Nutr, 125(6) :1484-9 1995 Jun
    
16. Ray, O. and Ksir, C. Drugs, Society and Human Behavior, Mosby, 1990, chapter 9
    
17. Vander, Sherman and Luciano Human Physiology
    
18. Werbach, M. (1988) Nutritional Influences on Illness. New Canaan, CT: Keats Publishing.
    
19. Williams, Sue R. (1993) Nutrition and Diet Therapy, seventh edition. St. Louis: Mosby.
    
20. (Ritter, M. "Study Says Vitamin C Could Cut Liver Damage," Associated Press, October 11, 1986)
    
21. (Cathcart, Robert F. III (1981)
    
22. (1988) Nutritional Influences on Illness. New Canaan, CT: Keats Publishing.
    
23. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56:95–99.
    
24. Matsuyama Y, Morita T, Higuchi M, et al. The effect of taurine administration on patients with acute hepatitis. Prog Clin Biol Res 1983;125:461-468.
    
25. Yamori Y, et al. Studies on stroke prevention in animal models, and their supportable epidemiological evidence. As cited in H Barnett, et al., eds. Cerebrovascular diseases: new trends in surgical and medical aspects. Amsterdam: Elsevier/North Holland, 1981:47–62.
    
26. Franconi F, Bennardini F, Mattana A, et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: Effects of taurine supplementation. Am J Clin Nutr. 1995;61:1115–1119.
    
27. Marchesi GF, Quattrini A, Scarpino O, et al. Therapeutic effects of taurine in epilepsy: a clinical and polyphysiographic study [in Italian; English abstract]. Riv Patol Nerv Ment. 1975;96:166–184.
    
28. Fukuyama Y, Ochiai Y. Therapeutic trial by taurine for intractable childhood epilepsies. Brain Dev. 1982;4:63–69.
    
29. Podda M, Ghezzi C, Battezzati PM, et al. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology. 1990;98:1044–1050.
    
30. Azuma J, Sawamura A, Awata N, et al. Double-blind randomized crossover trial of taurine in congestive heart failure. Curr Ther Res. 1983;34:543–557.
    
31. Azuma J, Sawamura A, Awata N, et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol. 1985;8:276–282.
    
32. BioDrugs. 2001;15(7):465-89.
    
33. Bioorg Med Chem. 2004 Nov 1;12(21):5677-5687.
    
34. Life Sci. 1996;58(18):1591-600.
    
35. Biochem Pharmacol. 1994 Aug 17;48(4):753-9.
    
36. J Appl Toxicol. 1992 Dec;12(6):439-42.
    
37. J Appl Toxicol. 1990 Aug;10(4):275-9.
    
38. Fundam Clin Pharmacol. 1989;3(3):183-91.
    
39. FEBS Lett. 1985 Feb 25;181(2):291-4.
    
40. Biotechnol Ther. 1993;4(3-4):263-70.
    
41. Biol Res. 1994;27(2):105-12.
    
42. Drugs. 2001;61(14):2035-63.
    
43. Planta Med. 1989 Oct;55(5):417-9.
    
44. Z Phytother. 1991. 12:162-74 (in German).
    
45. Prog Clin Biol Res. 1986;213:319-31.
    
46. Hepatology. 1996 Apr;23(4):749-54.
    
47. Zhongguo Yao Li Xue Bao. 1989 Sep;10(5):414-8 (in Chinese).
    
48. Hepatology. 1992 Mar;15(3):373-81.
    
49. Gastroenterology. 1994 Jan;106(1):152-9.
    
50. Liver. 1982 Jun;2(2):77-81.
    
51. Med Welt. 1978 Jan 27;29(4):124-31(in German).
    
52. Scand J Gastroenterol. 1993 Jan;28(1):89-94.
    
53. Am J Gastroenterol. 1999 Jul;94(7):1818-22.
    
54. Cardiovasc Drugs Ther. 1995 Dec;9(6):779-84.
    
55. Int J Clin Pharmacol Ther. 1994 Feb;32(2):53-6.
    
56. Life Sci. 1997;61(19):1907-14.
    
57. Cas Lek Cesk. 1994 Jun 13;133(12):366-9 (in Czech).
    
58. Free Radic Biol Med. 1999 Mar;26(5-6):609-19.
    
59. "Short-Term Administration of (-)-Epigallocatechin Gallate Reduces Hepatic Steatosis and Protects Against Warm Hepatic Ischemia/Reperfusion Injury in Steatotic Mice," Ryan N. Fiorini, Jennifer Donovan, David Rodwell, Zachary Evans, Gang Cheng, Harold May, Charles E. Milliken, John Markowitz, Crystal Campbell, Julia K. Haines, Michael G. Schmidt, Kenneth D. Chavin, Liver Transplantation, 11:3; March 2005 (DOI: 10.1002/lt.20348).
    
60. Brand N. Cynara scolamus L –the artichoke [translated from German]. Z Phytother. 1990;11:169–175.
    
61. Brand N. Cynara scolamus L –the artichoke [translated from German]. Z Phytother. 1990;11:169–175.. Blumenthal M, ed. The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines. Boston, Mass: Integrative Medicine Communications;1998:84.
    
62. Kirchhoff R, Beckers CH, Kirchhoff GM, et al. Increase in choleresis by means of artichoke extract. Phytomedicine. 1994;1:107–115.
    
63. Kupke D, von Sanden H, Trinczek-Gartner H, et al. An evaluation of the choleretic activity of a plant-based cholagogue [translated from German]. Z Allgemeinmed. 1991;67:1046–1058.
    
64. Matuschowski P.Testing of Cynara scolymus in the isolated perfused rat liver. 43rd Ann Congr Soc Med Plant Res. Halle; Sept 1996:3–7.
    
65. Kupke D, von Sanden H, Trinczek-Gartner H, et al. An evaluation of the choleretic activity of a plant-based cholagogue [translated from German]. Z Allgemeinmed. 1991;67:1046–1058.
    
66. Englisch W, Beckers C, Unkauf M, et al. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung. 2000;50:260–265.
    
67. Kraft K. Artichoke leaf extract—recent findings reflecting effects on lipid metabolism, liver and gastrointestinal tracts. Phytomedicine. 1997;4:369–378.
    
68. Grogan, J. L., et al. “Potential hypocholesterolemic agents: dicinnamoyl esters as analogs of cynarin.” J. Pharm. Sci. 1972; 61(5): 802–3.
    
69. Bobnis, W., et al. “Case of primary hyperlipemia treated with cynarin.” Wiad. Lek. 1973; 26(13): 1267–70.
    
70. Pristautz, H., et al. “Cynarin in the modern management of hyperlipemia.” Wien Med. Wochenschr. 1975; 125(49): 705–9.
    
71. Montini, M., et al. “Controlled application of cynarin in the treatment of hyperlipemic syndrome. Observations in 60 cases.” Arzneimittelforschung 1975; 25(8): 1311–14.
    
72. Adzet T, Camarasa J, Laguna JC: Hepatoprotective activity of polyphenolic compounds from Cynara scolymnus against CCl4 toxicity in isolated rat hepatocytes. J Nat Prod. 50: 612, 1987.
    
73. Ernst E: Die Artischocke - eine Heilpflanze mit Geschichte und zukunftperspektive. Naturamed 10: 7, 1995. Fintelmann V: Antidyspeptische und lipidsenkende Wirkungen von Artischockenextrakt. Ergebnisse klinischer Untersuchungen zur Wirksamkeit und Vertraglichkeit von Hepar SL Forte an 553 Patienten. Z. Allg. Med. 72:48, 1996.
    
74. Fintelmann V: Therapeutic profile and mechanism of action of artichoke leaf extract: hypolipemic, antioxidant, hepatoprotective and choleretic properties. Phytomed. 1996. Suppl 1: 50.
    
75. Frohlich E, Zigler W: Uber die lipidsenkende Wirkung von Cynarin. Subsidia Medica 25 (3): 5, 1973.
    
76. Gebhardt R: Artischockenblatterextrakt: In vitro Nachweis einer Hemmwirkung auf die cholesterin-Biosynthese. Med. Welt 46: 348-35-, 1995.
    
77. Gebhardt R: Neue experimentelle Erkenntnisse zur Wirkung von Artischockenblatterextrakt. Z Allg. Med. 72: 20-23, 1996
    
78. Gebhardt R: Antioxidative and protective properties of extract from leaves of the artichoke (Cynara scolymnus L,) against hydro-peroxide-induced oxidative stress incultured rat hepatocytes. Toxicol Appl Pharmacol 144: 279-286, 1997
    
79. Gebhart R: Inhibition of Cholesterol Biosynthesis in Primary Cultured Rat Hepatocytes by Artichoke (Cynara scolymnus L.) Extracts. J Pharmacol Exp Ther 286: 3, 1998.
    
80. Gebhardt R, Fausel M, Henke B,: Polyphenols and flavonoids as antioxidant and hepatoprotective principles of artichoke extracts. Cell Biology and Toxicology, 1996.
    
81. Grace SC, Salgo MG, Pryor WA: Scavenging of peroxinitrite by a phenolic/peroxidase system prevents oxidative damage to DNA. FEBS Letters 426(1): 24-8, 1998.
    
82. Hammerl H, Kindler K, Kranzl C, Nebosis G, Pichler O, Studlar M: Uber den Einfluss von cynarin auf hyperlipidamien unter besonderer Berucksichtigung des types II (hypercholesterinamie). Wiener Med. Wschr. 41: 601-605, 1973.
    
83. Hammerl H, Pichler O: Uber eine moglichkeit der kausalen Behandlung von Erkrankungen der Gallenwege mit einem Artischockenpreparat. Wiener Med. Wschr. 107 (25/26): 545, 1957.
    
84. Hammerl H, Pichler O: Untersuchungen uber den Einfluss eines Artischockenextraktes auf die Serumlipide in Hinblick auf die Arterioskleroseprophylaxe. Wiener Med. Wschr. 109 (44): 853, 1959.
    
85. Held C: Artischocke bei Gallenwegsdyskinesien. Neue Aspekte zur Therapie mit Choleretika. Z. Klin. Med. 47:92, 1992.
    
86. Hemmerle H et al: Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J Medicinal Chemistry 40(2): 137-45, 1997.
    
87. Kirchhoff R, Beckers C, Kirchhoff GM, Trinczek-Gartner H, Petrowicz O, Reimann HJ: Increase in choleresis by means of artichoke extract. Results of a randomized placebo-controlled double-blind study. Phytomedicine 1: 107, 1994.
    
88. Kitts DD, Wijewickreme AN: Effect of dietary caffeic and chlorogenic acids on in vivo xenobiotic enzyme systems. Plant Foods for Human Nutrition 45(3):287-98, 1994.
    
89. Kono et al.: The supression of the N-nitrosating reaction by chlorogenic acid. Biochemical Journal 312(Pt3): 947-53, 1995.
    
90. Kono Y et al: Antioxidant activity of polyphenolics in diets. Biochimica et Biophysica Acta 1335(3): 335-42, 1997.
    
91. Kupke D, von Sanden H, Trinczek-Gartner H, Lewin J, Blumel G, Reimann HJ: Prufung der choleretischen Aktivitat eines pflanzlichen Cholagogums. Z. Allg. Med. (67): 1046, 1991
    
92. Lietti A: Choleretic and cholesterol lowering properties of two artichoke extracts. Filoterapia 48: 153,1977.
    
93. Maros T et al.: Wirkungen der Cynara scolymnus-Extrakte auf die Regeneration der Rattenleber. Arzneim-Forsch/(Drug Res) 18: 184, 1966.
    
94. McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE Jr: Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 42(1): 140-6, 1998.
    
95. Mori H, Tanaka T, Shima H, Kuniyasu T, Takahashi M: Inhibitory effect of chlorogenic acid on methylazoxymethanolacetate-induced carcinogenesis in large intestine and liver of hamsters. Cancer Letters 30(1):49-54, 1986.
    
96. Morishita Y et al.: Regressive effects of various chemopreventive agents on azoxymethane-induced aberrant crypt foci in the rat colon. Jpn J Cancer Res 88: 815-20. 1997
    
97. Petrowicz O, Gebhardt R, Donner M, Schwandt P, Kraft K: Effects of artichoke leaf extract on lipoprotein metabolism in vitro and in vivo. Atherosclerosis 129: 147, 1997.
    
98. Pittler MH, Ernst E: Artichoke leaf extract for serum cholesterol reduction. Perfusion (German journal) 11: 338-340, 1998
    
99. Robinson WE Jr, Cordeiro M, Abdel-Malek S, Jia Q, Chow SA, Reinecke MG, Mitchell WM: Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Molecular Pharmacology 50(4): 846-55, 1996.
    
100. Samochowiec L, Wojcicki J, Kadykow M: The influence of 1,5-dicaffeoylquinic acid on serum lipids in the experimentally alcoholized rat. Panminerva Med 13(11): 87,1971.
     
101. Samochowiec L: The action of herbs and roots of artichokes (Cynara scolymnus) and cardoon (Cynara cardunculus) on the development of experimental atherosclerosis in white rats. Diss. Pharm. 14: 115, 1962.
     
102. Tanaka T et al.: Inhibition of 4-nitroquinoline-1-oxide- induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids. Carcinogenesis 14(7): 1321-5, 1993.
     
103. Tixier L: Les actions physiologiques et therapeutique des Cynara Scolymnus. Presse med. 44:880, 1939.
     
104. Wojcicki J, Samochowiec L, Kosmider K: Influence of an extract from artichoke (Cynara sclymnus) on the level of lipids in serum of aged men. Herba Pol. 27: 265, 1981.
     
105. Wojcicki J: Effect of 1,5-dicaffeoylquinic acid on ethanol- induced hypertriglyceridemia. Arzneim-Forsch/Drug Res. 26 (11): 2047, 1976. Wojcicki J: Effects of 1,5-dicaffeoylquinic acid (cynarin) on cholesterol levels in serum and liver of acute ethanol-treated rats. Drug Alcohol Dep. 3: 143, 1978.
     
106. Atal CK, Sharma ML, Kaul A, Khajuria A. Immunomodulating agents of plant origin. I: preliminary screening. J Ethnopharmacol 1986;18:133-141.
     
107. Subedi BP. Plant profile: Kutki (Picrorhiza scrophulariifiora). Himalayan Bioresources 2000;4.
     
108. Weinges K, Kloss P, Henkels WD. Natural products from medicinal plants. XVII. picroside-II, a new 6-vanilloyl-catapol from Picrorhiza kuroa Royle and Benth. Justus Liebigs Ann Chem 1972;759:173-182. [Article in German]
     
109. Stuppner H, Wagner H. New cucurbitacin glycosides from Picrorhiza kurroa. Planta Med 1989;55:559-563.
     
110. Simons JM, `t Hart BA, Ip Vai Ching TR, et al. Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils. Free Radic Biol Med 1990;8:251-258.
     
111. Stuppner H, Wagner H. New cucurbitacin glycosides from Picrorhiza kurroa. Planta Medica 1989;55:559.
     
112. Russo A, Izzo AA, Cardile V, et al. Indian medicinal plants as antiradicals and DNA cleavage protectors. Phytomedicine 2001;8:125-132.
     
113. Chander R, Kapoor NK, Dhawan BN. Picroliv, picroside-I and kutkoside from Picrorhiza kurroa are scavengers of superoxide anions. Biochem Pharmacol 1992;44:180-183.
     
114. Chander R, Kapoor NK, Dhawan BN. Effect of picroliv on glutathione metabolism in liver and brain of Mastomys natalensis infected with Plasmodium berghei. Indian J Exp Biol 1992;30:711-714.
     
115. Chander R, Singh K, Visen PK, et al. Picroliv prevents oxidation in serum lipoprotein lipids of Mastomys coucha infected with Plasmodium berghei. Indian J Exp Biol 1998;36:371-374.
     
116. [11.] Singh V, Kapoor NK, Dhawan BN. Effect of picroliv on protein and nucleic acid synthesis. Indian J Exp Biol 1992;30:68-69.
     
117. [12.] Shukla B, Visen PK, Patnaik GK, et al. Choleretic effect of picroliv, the hepatoprotective principle of Picrorhiza kurroa. Planta Med 1991;57:29-33.
     
118. [13.] Visen PK, Saraswat B, Dhawan BN. Curative effect of picroliv on primary cultured rat hepatocytes against different hepatotoxins: an in vitro study. J Pharmacol Toxicol Methods 1998;40:173-179.
     
119. [14.] Rastogi R, Srivastava AK, Rastogi AK. Biochemical changes induced in liver and serum aflatoxin B1-treated male wistar rats: preventive effect of picroliv. Pharmacol Toxicol 2001;88:53-58.
     
120. [15.] Saraswat B, Visen PK, Patnaik GK, Dhawan BN. Ex vivo and in vivo investigations of picroliv from Picrorhiza kurroa in an alcohol intoxication model in rats. J Ethnopharmacol 1999;66:263-269.
     
     
     

1 2 3 4 5 6 7